Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe

This article was originally published in The Pink Sheet Daily

Executive Summary

Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.

You may also be interested in...



Biopure’s Hemopure BPAC Review To Be Closed-Door

The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel